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دللجا برع ةيجلاعلا ةرطسقلا ءانثأ تافعاضلما لآلم
س�ك�ف ثيك ،يداهلا ظيفح
 هتنراقمو دللجا برع ةراتخلما ةيجلاعلا ةرطش�قلا ءانثأا طبارلا ينهدلا بلقلا س�مح ينتوبرل لآالما ديدتحو ةيش�يخش�تلا ةميقلا ريدقت :فدهلا :ص�خللما
 برع ةيجلاع ةراتمخ ةرطش�ق ءارجإلا ىفش�تش�لما تلخدأا ةبقاعتم ةلاح  80 ىلع ةيقابتش�ا ةش�ارد تيرجأا :ةقيرطلا ةيرايعلما ةيبلقلا تامش�ا�لاب
 بلقلا س�مح و ،ينب�لج�يام ،)ب م( يننيتايركلا زينياك ةلتك ،)يآا( بلقلا ينن�بورت ،)ت( بلقلا ينن�بورت :ةيبلقلا تامش�ا�لا زيكرت ةش�ارد تم .دللجا
 ناك ةيبلقلا تامش�ا�لا زيكرت عافترا .ةعاش� نيسر�عو عبرأاو ةعاش� ةسر�ع تش�و تاعاش� عبرأاو ينتعاش�و ،ةعاش�ب اهدعبو ةرطش�قلا لبق طبارلا ينهدلا
 ينتورب :ةجيتنلا .ارهش�  26 – 20 ةدلم ىش�رلما ةعباتم تم ..ةيعوألال يعاعش�لا ري�ش�تلاو ةيلمعلاب قلعتت ىرخأاو ةيفارغ�يمد  تايرغتبم اطبترم
 نم ةترفلل ةيبلقلا ةطلجلل ركبلما س�يخش�تلل بش�نألاا ناكو ،ةرطش�قلا نم طقف ينتعاش� دعب كلذ و اعافترا عسر�ألاا ناك طبارلا ينهدلا بلقلا س�مح
 ينتورب ،)17.5%( ينب�لج�يام ،)46.25%( )يآا( بلقلا ينن�بورت :ةيلاتلا بش�نلاب ىرخألاا تامش�ا�لا تعفترا .ءاع�لا بأار دعب تاعاش� 3 – 1
 )يآا( بلقلا ينن�بورت ناك .)7.5%( )ت( بلقلا ينن�بورت و ،)11.25%( )ب.م( ينتايركلا زينياك ةلتك ،)13.3%( طبارلا ينهدلا بلقلا س�مح
،)P >0.02( رمعلا مدقت عم ةيبلقلا تامش�ا�لا عافترا طبترا .ىرخألاا تامش�ا�لا ينب لش�فألاا ناك و تافعاش�لما لك س�يخش�تل ةيش�اش�ح ثركألاا 
 تافعاش�لماو  ،)P <  0.019(  تاماعدلا  مادختش�او  ،)P >  0.003(  بلقلا  طيطخت  في  ةيوترلا  س�قن  تايرغت  عم  ةدالحا  ةيردش�لا  ملاآلااو  
 ةطللجا ثودح دنعو ،)P > 0.003( ةلطاعلا تاماعدلاو ،)P >0.022( تقؤ�لما ءاع�لا دادش�ناو ،)P > 0.004( يش�يئرلا خيلش�تلا لثم ىبركلا
 )20.67( ب ةنراقم ارهش� )16.92( تافعاش�م نودب ءاقبلا لدعم س�افخنا عم اقفاترم ناك ةيبلقلا تامش�ا�لا عافترا .)P > 0.042( ةيبلقلا
 اهثودح نم ةعاش� دعب ةيبلقلا ةطلجلل ركبلما س�يخش�تلا طبارلا ينهدلا بلقلا س�مح ينتورب ةعاطتش�اب ن�كي دق :ةص�لالخا .)P > 0.03 (ارهش�
 ينن�بورت س�ايق متي نأاب حش�نن .ةيجلاعلا ةرطش�قلا ءانثأا ةيش�يئرلا تافعاش�لما  س�يخش�ت ىلع ةردق ثركألاا �ه )يآا( بلقلا ينن�بورت .)اهدعب وأا(
 .)ةعاش� 24 - 16( ةترفب ةيجلاع ةرطش�ق لك دعب )يآا( بلقلا
.بلقلا ينن�بورت ،ةيبلقلا تامش�ا�لا ،طبارلا ينهدلا بلقلا س�مح ،ةيبلقلا ةطللجا ،ةيجلاعلا ةرطش�قلا :تاملكلا حاتفم
abstract: Objectives: The aim of this study was to assess the diagnostic and prognostic value of heart-type fatty 
acid-binding protein (H-FABP) in elective percutaneous coronary intervention (PCI) and compare it with standard 
cardiac markers. Methods: A prospective evaluation was done of 80 consecutive patients admitted for elective PCI. 
Serum cardiac troponin T (cTnT), cardiac troponin I (cTnI), creatine kinase-MB (CK-MB mass), myoglobin, and 
H-FABP were determined pre-angioplasty and 1, 2, 4, and 16–24 hrs post-angioplasty. Elevated cardiac markers 
were correlated with demographic, angiographic and procedural variables. Patients were followed up for 20–26 
months. Results: H-FABP peaked early at 2 hours and was useful for the early detection of evolving AMI within 1–3 
hours after angioplasty. Cardiac-TnI, myoglobin, H-FABP, CK-MB mass, and cTnT concentrations were elevated 
in 46.25%, 17.5%, 13.3%, 11.25%, and 7.5% respectively. Cardiac-TnI was the most sensitive marker for detecting all 
complications and was superior to all other markers. Elevated cardiac markers were correlated with old age (P < 
0.02); chest pain ± ECG changes of ischaemia (P < 0.003); use of stents (P  < 0.019) and major complications such 
as major dissection (P < 0.004); transient vessel closure (P < 0.022); bail out stent (P < 0.003), and AMI (P < 0.042). 
Elevated cardiac markers were associated with a reduction of event-free survival (16.92 versus 20.67 months, P < 
0.03). Conclusion: Heart-type-FABP measurements at 1 hour (or thereafter) post-PCI may offer an early chance of 
detecting evolving AMI; cTnI was the most sensitive marker for the detection of major complications in patients 
undergoing PCI. Measurements of cTnI 16–24 hours post-PCI should be part of the routine management of patients 
following elective PCI.
Keywords: Percutaneous coronary intervention; PCI; Acute coronary syndrome; Heart-type fatty acid-binding 
protein; Cardiac markers; Cardiac troponins; Complications.
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Percutaneous coronary intervention (PCI) is widely used in the treatment of many patients with stable angina, unstable 
angina (UA), recurrent angina after coronary artery 
bypass grafting (CABG), and acute myocardial 
infarction (AMI).1-3 PCI  is, in general, a safe 
procedure; however, occasionally complications 
occur, including AMI (3–5%),1-2 emergency CABG 
(3–7%),4 and death (0.9%).5 These events are usually 
caused by extensive arterial dissection, intracoronary 
thrombosis, or both, with resultant vessel occlusion. 
Acute closure occurs in 2–8% of patients undergoing 
PCI.6 In 75% of patients with abrupt closure, it occurs 
within minutes, in the other 25% it usually occurs 
within 24 hours.7 Ultrasound imaging has shown 
that dissection of the arterial wall is detected in 50–
80% of patients who have undergone successful PCI.8 
Other complications of PCI include coronary vessel 
rupture or injury, re-stenosis, arrhythmias, coronary 
artery spasm/elastic recoil, and embolism.9 Side 
branch occlusion occurs in 5% of side branches that 
are adjacent to a dilated coronary stenosis.10 
Uncomplicated angioplasty is not associated with 
any significant release of cardiac markers;11 however, 
more sensitive cardiac markers have increased the 
numbers of patients diagnosed with myocardial 
injury after PCI. These infarclets have been associated 
with increased risk of future complications.12-14 
Minor increases of creatine kinase-muscle and brain 
(CK-MB) after an apparently successful coronary 
intervention have been reported in 11.5–26% of 
cases, and have been associated with an increased 
risk of cardiac death and AMI during follow-up.12,15 
Serum cardiac troponin I (cTnI) and cardiac troponin 
T (cTnT) elevations have been detected in 13–44% 
of patients undergoing PCI.14,16-17 An increased cTnT 
concentration post-PCI has been correlated with 
a higher incidence of complex lesion morphology 
during angioplasty.18
Heart-type fatty acid-binding protein (H-FABP) 
has been found to be a useful early marker for 
the detection of myocardial injury.19 The value of 
H-FABP as an early marker for the identification 
of myocardial damage during PCI has not yet been 
studied. The aims of the study were to examine the 
relation between elevations of cardiac markers post-
PCI and complication rates during and after PCI 
and to determine whether elevated cardiac markers 
post-PCI are related to demographic, angiographic 
or procedural variables.
Methods
The study population consisted of a consecutive 
series of 80 patients recruited from the Cardiology 
Unit at the Royal Infirmary of Edinburgh over an 
eight month period in 2002. Ethical approval for the 
study was obtained from the local ethical committee 
and written informed consent was obtained from 
each patient. Thereafter, five serial blood samples 
were collected from each patient at 0 hour (base 
line concentration, pre-angioplasty) and at 1 hour, 
2 hours, 4 hours and 16–24 hours after angioplasty. 
The study group consisted of patients who were 
referred for elective angioplasty for both stable 
angina pectoris and UA. Patients who had a non-
elective angioplasty (e.g. rescue angioplasty, primary 
angioplasty, salvage angioplasty, or emergency 
angioplasty) were excluded from this study. Patients 
were categorised into two main groups according 
to the presence (cTnI positive) or absence (cTnI 
negative) of elevated cTnI concentrations ≥ 0.18 
µg/L. The two groups were compared with respect 
to demographic, angiographic and procedural 
Advances in Knowledge 
1. This article highlights the fact that the release of cardiac markers after percutaneous coronary intervention (PCI) is not uncommon and 
is associated with increased rate of future complications and reduction of event-free survival.
2. This article is the first of its kind to study the value of H-FABP in patients undergoing PCI and to evaluate its role in the diagnosis and 
prognosis of complications during and after PCI.
3. This study provided a standardised setting to compare and contrast the ability of the different cardiac markers available in clinical use 
today to detect myocardial damage post PCI.
Application to Patient Care
1. This study will help health care professionals select the most appropriate early test for the diagnosis of suspected AMI in patients with 
acute chest pain post PCI.
2. This article recommends the introduction into clinical practice of routine measurements of cTnI after all elective PCI procedures. This 
will guide the estimation of myocardial damage, which is sometimes not obvious clinically, and may guide further management with 
antiplatelet therapy.
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variables, and the frequency of complications 
during PCI and the in-hospital period. Patients 
were followed-up for 20–26 months after discharge 
from hospital and the numbers of cardiac events in 
each group were compared. Angiographic success 
was defined according to the European Society of 
Cardiology Task Force Guideline on Angioplasty as 
< 20% residual diameter stenosis and thrombolysis 
in myocardial infarction (TIMI) 3 flow.20 Clinical 
success was defined as angiographic success without 
in-hospital complications (death, AMI, emergency 
CABG, or ischaemia driven repeat PCI).
Cardiac-TnI, CK-MB mass, and myoglobin were 
analysed on a Stratus CS analyser machine (Dade 
Behring, Germany), using commercially available test 
materials. The coefficients of variations for cTnI were 
6.8%, and 6.7% at concentration range 0.24–0.36µg/L, 
and 4.6–6.9 µg/L respectively. Heart-type-FABP was 
analysed by an enzyme linked immunosorbent assay 
method using commercially available assays (Hycult, 
Table 1: Demographic and angiographic data of patients with and without elevated serum cardiac troponin I 
(cTnI). Continuous variables are presented as mean ± SD and categorical variables are presented as percentages 
(in brackets).  
Demographic data cTnI positive group (n = 37) cTnI Negative group (n = 43) P value
Age (yrs ± SD) 64.35 ± 9.22 59.1 ± 7.47 0.02
Male
Female
26 (70)
11  (30)
33 (77)
10 (23)
NS
NS
Type of preceding angina
Stable angina
Unstable angina
Atypical angina
19 (51)
14 (38)
4 (11)
26 (43)
17 (40)
-
NS
NS
-
risk Factors
Smoking
Diabetes Mellitus
Hypercholestrolaemia
Hypertension
Family history of IHD
24 (65)
3  (8)
27 (73)
18 (49)
16 (43)
27 (63)
8 (19)
37 (86)
14 (33)
23 (53)
NS
NS
NS
NS
NS
Previous Cardiac Events
Previous PCI
Previous CABG
Previous AMI
10 (27)
4 (11)
15 (41)
16 (37)
3 (7)
14  (33)
NS
NS
NS
Angiographic data cTnI positive group (n = 37) cTnI Negative group (n = 43) P value
Type of CAD
Single vessel CAD
Multiple vessel CAD
6 (16)
31 (84)
14 (33)
29 (67)
NS
NS
Anatomic site of PCI
LAD
LCX
RCA
Vein grafts
27 (73)
11 (30)
6 (16)
1 (3)
29 (67)
14 (32)
4 (9)
3 (7)
NS
NS
NS
NS
Multiple vessel PCI 5 (14) 6 (14) NS
left ventricular EF (% ± SD) 62 ± 12 65 ± 14 NS
Clinical success) 27 (73) 41 (95) 0.013
Angiographic success 30 (81) 41 (95) 0.04
Legend: cTnI = cardiac troponin I; P = probability value; IHD = ischaemic heart disease; PCI = percutaneous coronary intervention; CABG = 
coronary artery bypass grafting; AMI = acute myocardial infarction; CAD = coronary artery disease;  LAD = left anterior descending artery; LCX 
= left circumflex artery; RCA = right coronary artery; EF = ejection fraction;
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Cambridge, UK). The analytical sensitivity of H-FABP 
mean ± 2SD was 0.206 ± 0.047 µg/L. Cardiac-TnT 
was analysed on Elecsys 2010 using commercial 
assays (Roche, Germany). The reference ranges 
quoted by the manufacturer for CK-MB mass, cTnI, 
myoglobin, cTnT, and H-FABP assays were validated 
by assaying the reference ranges of 20 healthy blood 
donors samples (10 males and 10 females, mean 
age ±SD = 63.8 ±8.01, range 53–75 years, median = 
65 years). The mean ± SD concentrations of these 
markers were CK-MB mass =1.52 ± 0.8 µg/L, cTnI 
= 0.015 ± 0.006 µg/L, myoglobin = 41.5 ± 13.3 µg/L, 
cTnT = 0.011 ± 0.002 µg/L, and H-FABP = 6.86 ± 
2.21 µg/L. The optimal cut-off concentrations of 
cardiac markers were based on receiver operating 
characteristic (ROC) curve analysis between patients 
with and without complications after PCI, and also 
considerations of cardiac markers concentrations 
in the normal healthy blood donor group, the 
control group, and the basal or pre-angioplasty 
concentrations. The following cut-off concentrations 
were used to indicate myocardial injury following 
angioplasty (cTnI ≥ 0.18 µg/L; cTnT ≥ 0.1 µg/L; 
CK-MB mass ≥ 5 µg/L; myoglobin ≥ 95 µg/L, and 
H-FABP ≥ 16 µg/L). All these cut-off concentrations 
were associated with statistically significant areas 
under the curve (P < 0.0005). 
Statistical analyses were performed using the 
Statistical Package for Social Sciences (SPSSTM, 
Pittsburgh, statistical software, Version 12). 
Continuous variables were presented as mean ± SD. 
Comparisons between cTnI positive and negative 
groups demographic, angiographic and procedural 
variables were conducted by the Mann-Whitney U 
test for continuous variables and chi-square or Fisher’s 
exact test for categorical variables. Comparison of 
the mean concentrations of serial cardiac markers 
changes at 0 hour (before angioplasty) and at 1, 2, 
4, and 16–24 hours after angioplasty was conducted 
by the Friedman test. Significance was defined as a 
P value ≤ 0.05. The rate of event-free survival was 
estimated from the Kaplan-Meier survival method 
and was compared with the log rank test. 
Results 
The study group included 21 females (26%) and 59 
males (74%). The mean age of the group was 61.1 ± 
7.5 years. The control group (who had an angiography 
procedure alone without angioplasty) consisted of 
12 patients, 5 females and 7 males with a mean age 
61.9 ± 8.7 years. There were no significant releases of 
any of the cardiac markers in the control group (data 
not shown). This provides evidence that excludes 
diagnostic procedure as the cause of cardiac trauma 
and supports angioplasty as the primary cause of 
cardiac markers release. Cardiac-TnI was the most 
frequent abnormal marker and was therefore chosen 
for comparison in this study. In 37 out of 80 patients 
(46.25%), the cTnI concentration was ≥ 0.18 µg/L. 
An increase in cTnI concentration (> 0.06– ≤ 0.17 
µg/L) was observed in 22 patients (27.5%). The area 
under the curve (AUC) for cTnI was greater than 
that for other markers. Myoglobin was increased in 
14 (17.5%) patients, H-FABP in 13.3%, and CK-MB 
mass in 11.25%. In all cases where CK-MB mass, 
cTnT, H-FABP or myoglobin were elevated, cTnI 
was also elevated. 
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Legend: CK-MB = creatine kinase-muscle and brain mass; cTnI = serum cardiac troponin I; cTnT = serum cardiac troponin T; HFABP = heart-
type fatty acid-binding protein
Figure 1:  Serum cardiac markers before (0 hour), and at 1, 2, 4, and 16–24 hours after PCI in cTnI positive group. 
Data are presented as mean ± SD
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As compared with cTnI, cTnT was increased 
above the cut-off concentration in only 6 
(7.5%) patients, and five of them had significant 
complications. Cardiac-TnT was elevated to 
concentrations between 0.01–0.06 µg/L in 36 patients, 
and between ≥ 0.06 – < 0.1 µg/L in 4 patients. The 
complications reported in these two groups were 
in 10 and 3 patients respectively. All 6 patients with 
cTnT > 0.1 µg/L and the 13 patients in the last two 
groups had cTnI ≥ 0.18 µg/L. In the cTnI negative 
group (43 patients, 53.75%), no increase in cTnT or 
CK-MB mass above the cut-off concentration was 
observed. Myoglobin was elevated in two patients, 
and H-FABP (concentration = 21 µg/L) in one 
Table 2: Procedural variables in patients with and without elevated cardiac troponin I (cTnI). Continuous 
variables are presented as mean ± SD and categorical variables are presented as percentages (in brackets).
Procedure data cTnI positive group (n = 37) cTnI Negative group (n = 43) P value
Chest pain ± ECG changes of ischaemia 19 (51.4) 6 (13.9) 0.004
Procedure information
Number of lesions dilated (per patient)
Number of vessels dilated (per patient)
Balloon diameter (mm)
Total number of balloon inflation (n)
Total time of balloon inflation (minutes)
Maximum inflation time (seconds)
Maximum inflation pressure (Pa)
Total duration of procedure (minutes)
46 (1.24)
41 (1.11)
3.3 ± 0.56
6.4 ± 4.6
3.77 ± 4.18
50.12 ± 26
11.21 ± 3.34
56.9 ± 38.3
41 (1.24)
40 (1.21)
3.12 ± 0.45
4.81 ± 2.8
3.41 ± 2.86
55.24 ± 24.34
10.45 ± 3.56
42.31 ± 19.2
NS
NS
NS
NS
NS
NS
NS
NS
Major complications during PCI
Major dissection
Side branch occlusion
Transient vessel occlusion
Major technical failure
Bail out stent
10 (27)
5 (13.5)
7 (19)
1 (3)
7 (19)
1 (2)
2 (5)
1 (2)
0 (0)
0 (0)
0.004
NS
0.022
NS
0.003
Minor complications during PCI
Minor dissection
Coronary spasm/ elastic recoil
Minor technical failure
8 (21.6)
2 (5.4)
1 (3)
7 (16)
5 (12)
2 (5)
NS
NS
NS
Post-procedural complications (24h)
AMI
Angina with re-catheterisation
Angina without re-catheterisation
Emergency CABG.
3 (8)
5 (13.5)
1 (3)
0 (0)
0 (0)
1 (2)
2 (5)
0 (0)
0.042
NS
NS
-
Total number of stents 42 32 0.019
reason for stenting
Stent for dissection
Stent for sub-optimal result
Elective stent
Bail out stent
15 (40.5)
12 (32.4)
3 (8)
7 (19)
8 (17)
15 (35)
6 (14)
0 (0)
0.05
NS
NS
0.003
Use of IvUS during PCI 6 (16) 1 (2) 0.045
Post-procedural treatment
Ticlopidine
Clopidogrel
Abciximab + Ticlopidine
Abciximab + Clopidogrel
11 (30)
8 (22)
3 (8)
3 (8)
20 (47)
7 (16)
2 (5)
1 (2)
NS
NS
NS
NS
Legend: cTnI = cardiac troponin I; P = probability value; ECG = electrocardiogram; NS = not significant; mm = millimetre; Pa = Pascal; PCI = 
percutaneous coronary intervention; AMI = acute myocardial infarction; CABG = coronary artery bypass grafting
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patient. The release patterns of cardiac markers in the 
cTnI positive group are shown in Figure 1. The peak 
concentrations of H-FABP, myoglobin, cTnI, cTnT, 
and CK-MB mass were achieved at 2 hrs, 4–16 hrs, 
16–24 hrs, 16–24 hrs, and 16–24 hrs respectively. 
Eighteen patients had an increase in cTnI 
concentration alone. Eight patients had some 
complications during PCI, whereas in 6 patients 
no specific complications were reported. However, 
in these patients the angioplasty was described as 
technically difficult and prolonged or the lesion 
was complex, and three patients had failure of stent 
deployment, sudden drop of blood pressure after 
sheath removal, and limb ischaemia post-procedure. 
Two patients in this group had total occlusion of the 
vessels and two had ostial lesions. In four patients 
with cTnI elevations (range 0.18–0.65 µg/L), no 
specific complications were reported to explain this 
rise. 
The use of newer and potent antiplatelets 
treatment after PCI was liberal in this group 
of patients. Fifty-five patients (68%) received a 
combination of ticlopidine and/or clopidogrel 
and/or abciximab antiplatelets after stenting. The 
demographic and angiographic data of the cTnI 
positive and negative groups are shown in Table 1. 
Patients in the cTnI positive group were older (P 
< 0.02). Clinical and angiographic successes were 
reported more frequently in the cTnI negative group 
(95% versus 73%, P < 0.013), and (95% versus 81%, P 
< 0.04) respectively. Table 2 illustrates the procedural 
variables. There was a significant increase of the 
following in the cTnI positive group: chest pain ± 
ischaemic ECG changes during PCI (51.4% versus 
13.9%, P < 0.004); numbers of stents used (42 versus 
32, P < 0.019); and use of intravascular ultrasound 
during PCI (16% versus 2%, P < 0.045). There was 
no difference between the groups related to the 
total duration of PCI, the total numbers of balloon 
inflations per procedure, the number of lesions 
treated, balloon size, inflation time and pressure, 
or the antiplatelet regimes after PCI. The frequency 
and types of complications reported during and after 
PCI were significantly increased in the cTnI positive 
group. Out of the 37 patients in this group, 23 (62%) 
had complications compared to only 14 out of the 43 
patients (32.5%) in the cTnI negative group (P < 0.03). 
These complications included one or a combination 
of the following: major dissection (27%, P < 0.004); 
transient vessel occlusion (19%, P < 0.022); bail out 
Table 3. Cardiac events during follow up for ≥ 20 months. Except where otherwise indicated, numbers in brackets 
indicate percentages. 
Events cTnI (+) group (n = 37) cTnI (-) group (n = 43) P value
Angina control post-procedure
Worse
Better
Unchanged
10 (27)
20 (54)
7 (19)
10 (23)
30 (70)
2 (5)
NS
NS
NS
Cardiac event(s) during follow-up
Admitted with angina
Admitted with UA
Admitted with AMI
Admitted with Heart failure
Target vessel revascularisation
Non-target vessel revascularisation
Referred for CABG
Death
5 (14)
5 (14)
1 (3)
1 (3)
6 (16)
5 (14)
3 (8)
1 (3)
3 (7)
2 (5)
0
0
7 (16)
4 (9)
3 (7)
2 (5)
NS
NS
-
-
NS
NS
NS
NS
Total No. with uncontrolled angina 17 (46) 12 (28) NS
Total No. of patients with events 17 (46) 12 (28) NS
Total No. of  events per group 29 (78) 21 (48) NS
Average duration of follow-up (months) 22.6 ± 1.5 23 ± 1.2 NS
Patients lost to follow-up 0 1
Legend: cTnI = cardiac troponin I; P = probability value; NS = not significant; UA = unstable angina; AMI = acute myocardial infarction; CABG 
= coronary artery bypass grafting.
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stents (19%, P < 0.003); AMI (8%, P < 0.042); side 
branch occlusion (SBO) (13.5%, P = NS); major 
technical failure of equipment during angioplasty 
(3%, P  = NS); angina requiring re-catheterisation 
(13.5%, P  = NS); and minor dissection (21.6%, P  = 
NS). 
Forty-two stents were used in this group 
compared to 32 stents in the cTnI negative group. 
The increased frequency of stents in this group was 
mostly to treat dissections (40.5% versus 17%, P = 
0.05). Thirteen stents (31%) were used mostly on a 
bail-out basis to treat major dissection ± acute vessel 
closure. The use of stents for sub-optimal angioplasty 
results was slightly more in the cTnI negative group 
(49% versus 40.4%). Three patients developed AMI 
after PCI (1 Q wave and 2 non-Q wave AMI). The 
concentrations of cardiac markers in these patients 
were significantly elevated. H-FABP was the first 
marker to appear in significant concentrations after 
AMI. Peak concentrations of H-FABP, myoglobin, 
CK-MB mass and troponins occurred at 2 hours, 4 
hours, 16–24 hours, and 16–24 hours respectively 
after angioplasty. The release patterns of cardiac 
markers were similar to the release patterns seen in 
Figure 1. H-FABP reached diagnostic concentrations 
for AMI 1–2 hours post-angioplasty. The diagnosis 
of AMI based on myoglobin, CK-MB mass, and 
troponins was established at 2–4, 4–16, and 4–16 
hours respectively. Five patients had SBO during 
angioplasty. In 3 patients, this complication followed 
an extensive dissection. Out of the 5 patients, two 
developed AMI, two had considerable chest discomfort 
and ST segment depression ± T wave inversion, and 
in one patient the SBO was asymptomatic. Cardiac-
TnI concentration was elevated in all patients. 
The mean cTnI increase in these three groups was 
14.7 µg/L, 1.73 µg/L, and 0.18 µg/L respectively. 
Creatine kinase-MB mass, and myoglobin were 
increased in three patients, whereas H-FABP and 
CTnT were increased in two patients only. In the cTnI 
negative group, two patients had asymptomatic SBO, 
but there was no increase in cardiac markers in any 
of them. Forty-three patients had cTnI < 0.18 µg/L. 
Fourteen patients (32.5%) in this group developed 
complications during PCI; however, the frequency 
and severity of complications in this group were 
considerably lower than the cTnI positive group. 
These complications included one patient with 
major dissection, two patients with transient SBO, 
and one patient with transient vessel closure. The 
types of complications reported in the remaining 10 
patients were minor dissections, coronary spasm, 
elastic recoil, and minor technical problems.
After discharge, clinical follow-up was possible 
in 79 out of 80 patients (98.75%). The mean follow-
up period was 22.3 ± 1.7 months (range 20–26 
months). The incidence of adverse clinical events 
is summarised in Table 3. Patients who had cTnI 
elevation post-PCI had a non-significant higher 
incidence of complications (angina pectoris, UA, 
and non-target vessel revascularisation). The total 
number of clinical events per group in the cTnI 
positive and cTnI negative group was 29/37 (78%) 
versus 21/43 (48%) respectively, P = NS. Three 
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Figure 2:   Kaplan-Meier event-free survival analysis for the two groups of patients with cardiac troponin I (cTnI +) 
and without (cTnI -) elevations during angioplasty.
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patients who were included in the cTnI negative group 
had several adverse clinical events during follow-up 
(worsening of their angina, target and non-target 
vessel PCI, and CABG), despite uneventful PCI. 
Their cTnI concentration was between 0.08–0.11 
µg/L. Surprisingly, cTnT was highly predictive of the 
need for CABG on long-term follow-up. Fifty per 
cent of patients with elevated cTnT after PCI were 
referred for CABG compared to only 4% of patients 
with normal cTnT after PCI (P < 0.004). There were 
no other statistical differences between the cTnT 
positive and negative groups when other cardiac 
events were compared between the two groups. 
The time-dependent effect of post-procedural cTnI 
elevation on late clinical outcome was assessed using 
the Kaplan-Meier survival analysis. There was a 
significant decrease in event-free survival with more 
recurrent angina, myocardial infarction, repeat PCI, 
and CABG in the group of patients who had cTnI 
elevations during angioplasty [Figure 2]. The mean 
event-free survival for the group with cTnI elevation 
and those without cTnI elevation was 16.92 months 
(standard error (SE) = 1.66, 95% confidence interval 
(CI) = 13.67–20.18, median = 23 months) versus 
20.67 months (SE = 1.64, 95% CI = 17.46–23.88, 
median = 27 months) respectively (P < 0.03). Event-
free survival was also decreased in cTnT and H-FABP 
positive groups. There were no event-free survival 
differences when CK-MB mass or myoglobin positive 
and negative groups were compared.
Discussion 
The frequency of cTnI increases post-PCI in 
patients with complications was much higher than 
that seen with myoglobin, CK-MB mass, H-FABP, 
and cTnT. Cardiac-TnI was the most useful marker 
for the detection and quantification of PCI related 
complications. This reflects the superior sensitivity of 
cTnI for the detection of small releases of myocardial 
proteins after PCI. Heart-type-FABP was the earliest 
marker that could detect evolving AMI post-
PCI within 1–2 hours and the concentration had 
returned to normal within 16–24 hours. H-FABP 
may be a potential early marker that can help select 
patients with chest pain, in the early post-PCI period, 
for early investigations to ascertain the diagnosis of 
AMI. There were different rises of concentrations of 
cTnI and other markers and different symptoms in 
the various subgroups of patients with SBO. These 
differences may be related to the size of the side branch 
vessel, the extent of collaterals, and the duration of 
the occlusion. The occurrence of asymptomatic SBO, 
and also the absence of the rise of concentration of 
cardiac markers following documented SBO has 
been reported by others.10,13 Cardiac markers were 
also increased in the groups that had more stents 
and intravascular ultrasound investigations. Cardiac 
marker concentrations are elevated in some patients 
after PCI procedures involving stenting.21 However, 
this increase indirectly reflects more complications, 
for example dissection in this group. It is not clear 
whether the use of intravascular ultrasound during 
PCI contributes to myocardial injury or merely 
reflects underlying complications. 
Cardiac-TnI was increased in a small numbers of 
patients who had no complications reported during 
PCI. This may be due to: 1) the formation of small 
thrombi at the angioplasty site that may subsequently 
embolise to small distal arteries leading to small 
areas of focal necrosis; 2) the inability of contrast 
angiography to detect complications (indeed, 
intravascular ultrasound has been shown to be much 
more sensitive for the detection of coronary dissection 
after PCI compared with contrast angiography: 83% 
versus 27%;8 3) the variability of observers reporting 
complications and 4) mechanical trauma to the 
heart caused by guide wires manipulations within 
the coronary arteries. In our study, we found no 
apparent explanations for cTnI increases in 27% of 
patients, which was comparable to data published 
by Garbarz et al. who reported a 34% increase 
in cTnI concentrations in their study, which was 
not accounted for by complications during PCI.22 
The increases in cTnI, cTnT, CK-MB mass in the 
group with SBO was in agreement with Genser et 
al., who reported an increase in these markers in 
patients with SBO even when this complication was 
asymptomatic.13
The total frequency of cTnI rise (46.25%) in this 
study was slightly higher than that reported elsewhere 
in the literature. This could be explained by the use 
of cTnI sensitive assays with a relatively low cut-off 
concentration (≥ 0.18 µg/L) to indicate myocardial 
injury post-PCI. The frequency of CK-MB mass 
elevation in our study (11.25%) was lower than that 
reported previously (15–26%). This could be related 
to differences in assay methods used. Kugelmass et 
al. reported elevated CK-MB in 11.5% of patients 
following elective PCI, with no clinical sequels over 
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two years follow-up.15 However, in a small subset 
with a greater elevation of CK-MB, there was a trend 
towards decreased late survival compared to patients 
without CK-MB elevation. They also reported 
common CK-MB elevation after coronary stenting.15 
An increased frequency of cardiac events on long-
term follow-up (angina, PCI, CABG) was noticed in 
some patients who had very small increases of cTnI 
concentration (0.08–0.1 µg/L), which suggests that 
even small increases of cTnI may have a significant 
prognostic value and may reflect more diffuse or 
extensive CAD. 
Long-term complications in patients with 
elevated cardiac markers post-PCI have been 
suggested by Abdelmeguid et al. who reported more 
frequent and more serious complications (e.g. death 
and AMI).12 These differences could be related to 
several factors. First, the follow-up period in our 
study was relatively short compared to the study 
by Abdelmeguid (3–5 years, in some patients up 
to 8.5 years). Second, The use of stents was more 
frequent in the group of patients with elevated 
cardiac markers concentrations, which may alter 
the short-term risk of further progression to more 
serious complications.23 Third, the use of newer 
and more potent antiplatelets regimes (clopidogrel, 
abciximab) was also high in our study. The clinical 
benefit of these antiplatelets compounds in reducing 
the progression to AMI and death in patients with 
myocardial injury is well-established.24 Despite 
the fact that there were no statistically significant 
differences between the numbers of events, there was 
still a significant difference with respect to event-free 
survival between groups with and without elevations 
of these markers after angioplasty.
Increases in cTnT after PCI had been described 
previously.17,21 Ravkilde et al. found moderate 
increases in CK-MB mass in 6 of 23 patients (26%) 
undergoing visually successful PCI, whereas only 
3 (13%) showed cTnT elevation.17 In this study, 
the percentage of positive cTnT results after PCI 
was only 7.5% using a third generation cTnT assay 
that was very sensitive (< 0.01 µg/L) and specific. 
Some of the previous studies used a lower cut-off 
concentrations e.g. ≥ 0.04 µg/L or ≥ 0.06 µg/L, to 
indicate the presence of myocardial injury post-
PCI.18,25 Increased cTnT ≥ 0.06 µg/L has also been 
found to be associated with increased risk of death 
and AMI (10.5%) compared to cTnT ≤ 0.06 µg/L.25 
Based on ROC curve analysis, a cut-off concentration 
of cTnT ≥ 0.06 µg/L was slightly more sensitive and 
equally specific to cTnT ≥ 0.1 µg/L for the detection 
of complications. Depending on whether the cut-off 
concentration used was ≥ 0.1 µg/L or ≥ 0.06 µg/L, 
the frequency of abnormal cTnT elevations was 7.5% 
and 12.5 % respectively. Despite the low sensitivity 
of cTnT, the specificity and positive predictive value 
for the detection of complications was very high. 
Event-free survival of patients with elevated cTnT 
concentrations was significantly lower than those 
without cTnT elevations after angioplasty. Cardiac-
TnT was also associated with increased risk of 
CABG on long-term follow-up thus validating the 
prognostic significance of cTnT elevations post-PCI.
Measurements of cardiac markers post-PCI 
will be a useful adjunct to angioplasty and will help 
detect patients with subtle myocardial damage and 
may guide further management. Twelve patients 
(32%) with elevated cTnI in our study did not receive 
any form of antiplatelets (other than aspirin) during 
or after PCI. The cTnI concentrations range in these 
patients were 0.18–2.12 µg/L. Eight out of these 12 
patients had worsening of their angina or further 
cardiac events during follow-up. 
Conclusion
Heart-type-FABP measurements at 1 hour (or 
thereafter) post-PCI in patients with suspected 
complications may offer the best early chance of 
detecting evolving AMI. Cardiac-TnI has emerged 
as the most sensitive marker for the detection of 
major complications in patients undergoing PCI. 
It offers a reliable detection of myocardial damage 
that is sometime not obvious by visual assessment 
alone. The adjunctive measurements of cardiac 
markers post-PCI could help identify certain groups 
with elevated cardiac markers concentrations that 
might benefit from long-term treatment with newer 
antiplatelets therapy. Measurements of cTnI 16–24 
hours post-PCI should be part of the work-up 
management of patients following elective PCI.
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